Co-circulation of influenza a(H1N1)pdm09 and influenza a(H3N2) viruses, world health organization (WHO) european region, october 2018 to february 2019
Segaloff, H., Melidou, A., Adlhoch, C., Pereyaslov, D., Robesyn, E., Penttinen, P., Olsen, S.J.
Expert opinion on rotavirus vaccination in infancy
ECDC has published an Expert Opinion on rotavirus vaccination in infancy. The paper provides EU/EEA Member States with relevant scientific information on burden of rotavirus disease, vaccine effectiveness and safety, and cost-effectiveness studies to support the decision-making process on the possible introduction of routine vaccination of children against rotavirus gastroenteritis.
Seasonal influenza vaccination in Europe – Vaccination recommendations and coverage rates for eight influenza seasons (2007–2008 to 2014–2015)
Vaccination recommendations and coverage rates in the EU Member States for eight influenza seasons: 2007–2008 to 2014–2015.
Seasonal influenza vaccination in Europe – Vaccination recommendations and coverage rates for 2013-14 and 2014-15
Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013–14 and 2014–15 influenza seasons.
Seasonal influenza vaccination in Europe – Vaccination recommendations and coverage rates for 2012–13
This report provides an update on seasonal influenza immunisation policies and vaccination coverage rates in EU/EEA Member States for the 2012–13 influenza season.
Public health guidance: Seasonal influenza vaccination of children and pregnant women
The aim of this guidance document is to provide EU/EEA Member States and EU bodies with relevant information to make an informed decision on routine vaccination of healthy children and pregnant women with seasonal influenza vaccine. The options presented in this document are based on a systematic review of the literature and the opinions of a group of independent experts.
Expert opinion on priority risk groups for influenza vaccination
This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.